摘要
研究蒲元和胃胶囊联合三联杀菌药物对胃-十二指肠溃疡患者幽门螺杆菌(Hp)根除率及愈合质量的影响。方法:选取2014年1月—2015年12月期间本院收治的82例患者作为研究对象,将所有患者根据治疗方法分为两组:观察组40例(蒲元和胃胶囊+奥美拉唑+克拉霉素+阿莫西林),对照组42例(奥美拉唑+克拉霉素+阿莫西林),治疗持续2周后,两组患者继服奥美拉唑2周,总疗程4周。比较两组患者治疗后的溃疡愈合率、幽门螺杆菌根除率及治疗有效率,比较患者治疗6个月后Hp再感染率及溃疡复发率。结果:观察组患者愈合率为92.50%(37/40),Hp根除率97.50%(39/40),治疗有效率100.00%(40/40);对照组分别为76.19%(32/42),88.10%(37/32)及73.81%(31/42),差异具有统计学意义(P<0.05)。6个月后,观察组Hp再感染率10.00%(4/40),复发率0.00%(0/40);对照组分别为23.81%(10/42)及2.38%(1/42),差异无统计学意义(P>0.05)。结论:蒲元和胃胶囊联合三联抗菌疗法可以有效提高胃-十二指肠溃疡患者溃疡愈合质量及Hp根除率。
Objective : To study the influence of Puyuan Hewei Capsule combined with triple therapy on eradication rate of H. pylori(Hp) and healing quality in patients with gastroduodenal ulcer. Methods:From January 2014 to December 2015,82 patients were chosen as study objects, and all of them were divided into 2 groups : 40 patients in study group ( Puyuan Hewei Capsule + omeprazole + clarithromycin + amoxicillin) and 42 patients in control group ( omeprazole + clarithromycin + amoxicillin). After 2weeks, two groups took omeprazole for 2 weeks,total course of 4 weeks. After 4 weeks, the healing rate, eradication rate of Hp and effect rate were compared between two groups and the re - infection rate and recurrence rate of two groups were compared after 6 months. Results:In study group, the healing rate was 92.50% (37/40), the eradication rate of Hp was 97.50% (39/40)and effect rate was 100.00% (40/40). These of control group were respectively 76. 19% (32/42), 88. 10% (37/32)and 73.81% (31/ 42 ). The difference had statistical significance (P 〈 0.05 ). In study group, the re - infection rate was 10.00% (4/40)and the re- currence rate was 0.00% (0/40). These of control group were respectively 23.81% (10/42) and 2.38% (1/42). The difference had no statistical significance (P 〉 O. 05 ). Conclusion:Puyuan Hewei Capsule combined with triple therapy could help increase the eradication rate of Hp and healing quality in patients with gastroduodenal ulcer.
出处
《辽宁中医杂志》
CAS
北大核心
2017年第4期803-805,共3页
Liaoning Journal of Traditional Chinese Medicine
基金
国家重大新药创制科技重大专项课题(2009ZX09502-015)